[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"embryo-implantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:embryo-implantation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100627987","experimental-study-on-the-use-of-intrauterine-infusion-of-autologous-platelet-rich-plasma-prgf-iui-in-patients-with-recurrent-implantation-failure-andor-refractory-thin-endometrium-100627987",false,"NCT07455773","Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and\u002For Refractory Thin Endometrium","PMA_PREPAIRE STUDY: Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and\u002For Refractory Thin Endometrium.","PMA_PREPAIRE","Inclusion Criteria:\n\n* Female patients aged 18 to 45 years\n* Body mass index (BMI) between 18 and 30 kg\u002Fm\n* Undergoing assisted reproductive technology (ART) cycle with hormone replacement therapy\n* Endometrial thickness \\\u003C 7 mm after at least 10 days of hormone replacement therapy\n* History of at least one failed embryo transfer\n* Normal hematologic and biochemical laboratory results\n* Ability to understand and sign written informed consent\n\nExclusion Criteria:\n\n* Endometrial hyperplasia or uterine malignancy\n* Active pelvic inflammatory disease or untreated sexually transmitted infection\n* Coagulation disorders or platelet abnormalities\n* Thrombocytopenia (\\\u003C100,000\u002Fmm³)\n* Chronic anticoagulant therapy\n* Active systemic infection or immunodeficiency\n* Contraindications to intrauterine procedures","FEMALE","18 Years","45 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","Endometrial receptivity is a key determinant of success in assisted reproductive technology (ART). A significant proportion of patients experience repeated implantation failure despite euploid embryos and adequate laboratory conditions. Thin endometrium, often defined as ultrasound-measured thickness \\\u003C7 mm at embryo transfer, is frequently refractory to estrogen therapy and associated with low implantation and clinical pregnancy rates.\n\nPlatelet-Rich Plasma (PRP), obtained from autologous blood by double centrifugation, is rich in growth factors capable of stimulating cell proliferation, angiogenesis, and tissue regeneration, suggesting potential benefits for endometrial function. Preliminary studies indicate improved endometrial thickness and reproductive outcomes following intrauterine PRP infusion, but standardized protocols and systematic data are lacking.\n\nThe PMA\\_PREPAIRE study is a prospective, single-center, controlled, non-randomized interventional clinical trial conducted at the Reproductive Medicine Center of Cardinal Massaia Hospital, Asti. The study aims to evaluate the efficacy and safety of intrauterine infusion of autologous platelet-rich plasma (PRP), in association with hormone replacement therapy (HRT), in improving endometrial receptivity and reproductive outcomes in women with thin or refractory endometrium. The study includes a prospective control group treated with standard HRT alone.\n\nEligible women will be treated with standard clinical care, with PRP infusion offered to those with insufficient response to HRT. Inclusion criteria include age 18-45, BMI 18-30 kg\u002Fm², history of ≥1 failed embryo transfer, EMT \\\u003C5 mm after ≥10 days of HRT, and normal routine lab tests. Exclusion criteria include endometrial disease, recent gynecological infection, and systemic conditions such as thrombocytopenia or coagulopathies.\n\nProcedures include standard HRT from cycle days 1-2, serial ultrasound monitoring of endometrial thickness from days 6-8, intrauterine PRP infusion if EMT ≤7 mm (up to three infusions per cycle), embryo transfer once EMT ≥7 mm, and follow-up through pregnancy testing and confirmatory ultrasound.\n\nCollected data will be analyzed using descriptive statistics, paired and unpaired comparative analyses, and multivariate logistic regression models to evaluate predictors of treatment response and reproductive outcomes (significance level p \\\u003C 0.05).\n\nA sample size of 34 patients per group was estimated to detect a 1.5 mm difference in endometrial thickness (EMT) with 90% statistical power. Considering an anticipated dropout rate of 15%, a total of 40 patients per group will be enrolled.\n\nThe study includes:\n\nan intervention group consisting of 40 patients treated with HRT plus intrauterine PRP infusion; a prospective control group consisting of 40 patients with refractory thin endometrium treated with standard HRT alone, without PRP.",[28,29,30,31,32,33],"Recurrent Implantation Failure","Endometrial Receptivity Disorders","Embryo Implantation","Platelet-Rich Plasma","Platelet-rich Plasma (PRP)","Infertility, Female",[35,36,37,38,39,40],"Endometrial receptivity","Recurrent implantation failure","Assisted reproductive technology","Platelet-rich plasma","Intrauterine infusion","Autologous biological therapy","NOT_YET_RECRUITING","2026-05-12",{"date":44,"type":45},"2026-05-14","ACTUAL",{"date":47,"type":22},"2026-05-01",{"date":49,"type":22},"2027-12",{"name":51,"class":52},"Azienda Sanitaria Locale di Asti","OTHER_GOV",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":86},"100579237","phase-1-autologous-decidual-like-natural-killer-cells-therapy-for-infertility-or-adverse-pregnancy-history-100579237","NCT06821685","Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History","Clinical Study of Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History Caused by Abnormal Uterine Natural Killer Cells","Inclusion Criteria:\n\n* abnormal uterine NK cell function;\n* have one of the following medical history: unexplained recurrent spontaneous abortions (≥2 spontaneous abortions, including biochemical pregnancy), repeated implantation failure (failure of implantation of good-quality embryos in at least two IVF cycles), unexplained infertility, early-onset severe gestational hypertension or early-onset fetal growth restriction;\n* have clear fertility desires;\n* normal ovarian function or with frozen embryos;\n* edometrium thickness measured by vaginal ultrasound before ovulation or at mid-luteal phase \\>= 7mm;\n* 18kg\u002Fm\\^2 \\\u003C Body mass index \\\u003C 30kg\u002Fm\\^2;\n\nExclusion Criteria:\n\n* using progesterone receptor modulator;\n* chromosomal karyotype abnormalities in one spouse;\n* severe endometriosis, uterine fibroids affecting the shape of the uterine cavity or the size of the whole uterus more than 2 and a half months of pregnancy, uterine malformation, uterine adhesion or thin endometrium;\n* uncontrolled autoimmune diseases;\n* abnormal blood coagulation function, abnormal liver and kidney function, or other uncontrolled basic diseases (hypertension, diabetes, thyroid disease, etc.) that the researcher access which may affect the progress of the study;\n* history of pelvic malignant tumors;\n* currently participating in other clinical studies;\n* allergic to blood products.","22 Years","40 Years",{"count":63,"type":22},14,[65],"PHASE1","The aim of this study is preliminary exploration of the effectiveness and duration of autologous decidual-like NK cells therapy in improving uterine NK cells dysfunction.",[68,69,30,70],"Abortion, Habitual","Infertility Unexplained","Pre-Eclampsia",[72,73,74,75],"recurrent pregnancy loss","repeated implantation failure","unexplained infertility","decidual natural killer cells","RECRUITING","2025-11-13",{"date":79,"type":45},"2025-11-17",{"date":81,"type":45},"2025-02-13",{"date":49,"type":22},{"name":84,"class":85},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",1]